!"#$%&'()*+&,')-'!/ ' Gotz & Ittner., Nature Rev - - PDF document

▶
gotz ittner nature rev neurosci 9 532 2008 1 3 28 11
SMART_READER_LITE
LIVE PREVIEW

!"#$%&'()*+&,')-'!/ ' Gotz & Ittner., Nature Rev - - PDF document

May 16, 2023 282 likes •409 views

3/28/11 !"#$%&'()*+&,')-'.!/0' !"#$%&#'$()*+%,-./"+/%)0"-1)2-3%/)2-4/&%)5-)56/)7&+$+, ' !"#$%&'(&)#!*"+#,&-.(/( & 12%"3+&&)4 ,'54)-+,,)4'%"*'/#4+36)4 '

slide-1
SLIDE 1

3/28/11 1 !"#$%&'()*+&,')-'.!/0'

!"#$%&#'$()*+%,-./"+/%)0"-1)2-3%/)2-4/&%)5-)56/)7&+$+, '

!"#$%&'(&)#!*"+#,&-.(/( &

12%"3+&&)4’,'54)-+,,)4'%"*'/#4+36)4 ' 8$%'535/)0-")2/1-"9)81:#+"1/$5% ) #$4);/3"-&-(+,#&)*+%-"4/"% ' 7)862+4"'1%&#-)4"#%'79$:),#8$')"'.%$#&#%&'!&;2+#$+4<,'/#,+%,+0 ' 5%62=%9,'6)'>4+%6$+"6''

'

0*1&-23$45&

  • ?++*'@+A+4'%"#$%&'$)*+&,')-'62+'*#,+%,+B':%4C38&%4&9'62),+'

@%,+*')"'62+',:)4%*#3'D+4,#)"')-'62+'*#,+%,+'

  • ED+"'#"'%"#$%&'$)*+&,B'62+',))"+4'64+%6$+"6'@+F#",'62+'$)4+'

&#G+&9'62+'3)F"#CD+'#$:%#4$+"6,'%4+'#$:4)D+*'

  • >%4F+C"F'!H'%I+4')62+4':%62)&)F#+,',+6'#"B':%4C38&%4&9'

:2),:2)6%8'%"*'?.>':%62)&)F9B'*)+,'")6'4+,38+'3)F"#CD+' #$:%#4$+"6,'

  • 1)$@#"%C)"'62+4%:#+,'%4+'&#G+&9'6)'@+'4+J8#4+*'
  • 76+$'3+&&'%"*'#6,':)6+"C%&'-)4'!/'

!"#$%&'()*+&,')-'!/ '

Gotz & Ittner., Nature Rev Neurosci 9, 532 (2008)

slide-2
SLIDE 2

3/28/11 2

6$37#+&'28*+&9:;;*55*5<&927*&=>#7?+*5&

  • /+K"+'62+':%62):29,#)&)F#3%&'4+&%C)",2#:'@+6=++"'!H'%"*'

6%8'

  • /+6+4$#"+*'62%6'6%8'#,'"+3+,,%49'-)4'!HL$+*#%6+*'6)M#3#69'
  • N+A+4'%::4+3#%C)"'62%6',)&8@&+'-)4$,')-'!H'%"*'6%8'$%9'

:&%9'34#C3%&'4)&+,'8"*+4&9#"F'3)F"#CD+'*9,-8"3C)"O,9"%:C3' 6)M#3#69'

  • P*+"C-9'$%"9':)6+"C%&'")D+&'64+%6$+"6,'&#G+'!H'

#$$8")62+4%:9B'@86'64%",&%C)"%&'#,,8+,'%4+'$%"90'=2+"'6)' %*$#"#,6+4B'3)",+J8+"3+,')-'G+9'*#Q+4+"3+,'#"'28$%"' D+4,8,'4)*+"6'#$$8"+',9,6+$B'+63R'

@+3$3;#+&A"3#+&/35#??23$47*$45&

slide-3
SLIDE 3

3/28/11 3

Not all treatments work in mice

Intervention Effect on Pathology Effect on Cognition Nicotine Exacerbated tau Not determined Melatonin No improvement No improvement Resveratrol No improvement No improvement IGF1 No improvement No improvement High fat diet No change No change Copper Exacerbated Aß & tau pathology No change !2 agonists No effect on Aß, slight reduction of phosphotau No improvement Blueberry diet No improvement No improvement Lithium No effect on Aß pathology; Lower phosphotau No improvement

!4+'!H'>2+4%:#+,'>))'S#A&+OS%6+'-)4' !/T '

@2$;*"$5&B34.&'28*+5&

  • S%3G')-'3)"3)4*%"3+'@+6=++"':4+3&#"#3%&'$)*+&,'%"*'28$%"'

3&#"#3%&'64#%&,'U=4)"F'6%4F+6,B'=4)"F'$)*+&,B'&%3G')-'D%4#%@#&#69' %$)"F'#"*#D#*8%&,'#"'62+'$)*+&,B':%C+"6,'+"4)&&+*'6))'&%6+B'+63V'

  • W8$%",'+"4)&&+*'#"'3&#"#3%&'64#%&,'%4+'2+6+4)F+")8,B'=2+4+%,'

$),6'$)*+&,'8C&#;+'#"@4+*',6%#",')-'$#3+'

– ED%&8%C"F'")D+&'64+%6$+"6,'#"'$8&C:&+'&#"+,'$%9'2+&:'%**4+,,'62#,':)#"6 '

  • S%3G')-',8@,6%"C%&'"+84)"%&'%"*',9"%:C3'&),,'#"'62+'$%X)4#69')-'

4)*+"6'$)*+&,B'#"*#3%C"F'62+'$)*+&,'@+A+4'4+:4+,+"6'62+' :4)*4)$%&':2%,+')-'62+'*#,+%,+'

  • ()*+&,'%4+')-'-!/'%"*'$),6':+):&+'2%D+',!/'
slide-4
SLIDE 4

3/28/11 4

A"#$5+#C2$#+&@.#++*$D*5&

  • !/'#,'")6'3)$:&+6+&9'8"#-)4$'3&#"#3%&')4':%62)&)F#3%&'+"C69Y'

3)$:&#3%6+*'@9'&)"F':4)*4)$%&':2%,+'%"*')62+4'3)Z$)4@#*#C+,' %"*'%F#"F':4)3+,,'

  • [584+\'!/'#,'8"3)$$)"'

– $#M+*':%62)&)F9'3)$:&#3%6+,'64+%6$+"6'

  • >%4F+C"F'!H'%&)"+'%I+4')62+4':%62)&)F#+,',+6'#"B':%4C38&%4&9'

:2),:2)6%8'%"*'?.>,B'*)+,'")6'4+,38+'3)F"#CD+'#$:%#4$+"6,'

  • >4+%6$+"6,'%4+'#"+Q+368%&'%I+4'!H'%"*'6%8':%62)&)F9'*+D+&):0'

:%,,#D+'#$$8")62+4%:9Y'/W!Y'&#62#8$Y'$+*#3%&'-))*,B'+63R''

  • .)38,'"++*+*')"')62+4'*)=",64+%$'6%4F+6,R'
  • 24*$C#+&A#"D*45&E2"&6/&
  • !I+4'!H'%3CD%6+,'3%,3%*+B'-)38,'"++*,'6)'@+'*#4+36+*'%6')62+4'

*)=",64+%$'6%4F+6,R'

  • 5)6+"C%&'D#%@&+'6%4F+6,'

– >%8' – >4%",34#:C)"%&'UW/!1'#"2#@#6)4,V' – ?+84)64%",$#A+4,0'(]'4+3+:6)4,' – P"^%$$%C)"' – !86):2%F9OS9,),)$%&O54)6+%,)$%&',9,6+$' – ?+84):4)6+3CD+',64%6+F#+,' – 1+&&Z@%,+*'%::4)%32+,'

  • 1)$@#"%C)"')-'62+4%:#+,'#,'&#G+&9'4+J8#4+*'

>%8' 5%62)&)F9'

P"^%$$%C)"' 54)6+%,)$+' P$:%#4$+"6,' U12P5V' !86):2%F9' /#,48:6' _#"%,+O 52),:2%6%,+,' P$:+*+' !M)"%&'' >4%",:)46'

slide-5
SLIDE 5

3/28/11 5

&6/&&& & &&&&&@2$4"2+'

Advantages of Neural Stem Cells

  • 1. No ethical debate as

does not require destroying embryo.

  • 2. Transplanting neural

cells into neural tissue.

  • 3. Can differentiate neural

stem cells into neurons,

  • ligodendrocytes or

astrocytes.

slide-6
SLIDE 6

3/28/11 6 >+,C"F'76+$'1+&&,'-)4'!/ '

(84#"+'?71,'*+4#D+*'-4)$'5]'`.5'64%",F+"#3' $#3+'+M:4+,,'$%4G+4,')-'$8&C:)6+"39'

Haplotype-matched GFP-expressing transgenic mice from Mizumoto et al., 2003

?+84%&'76+$'1+&&,' P$:4)D+'(+$)49'#"'!F+*' !/'>4%",F+"#3'(#3+ '

slide-7
SLIDE 7

3/28/11 7

(),6'?71,'*#Q+4+"C%6+'#"6)'%,64)396+,' )4')&#F)*+"*4)396+, '

a"&9'%',$%&&'"8$@+4')-'`.5b' ' "+84)",'%4+'*+6+36+* '

(+4F+' `.5' '/1c'

?71,'+"F4%I'#"6)'62+'2),6'2#::)3%$:8,'

Dentate Gyrus Subiculum `4++"0'`.5'?71,' d+*0'!H':&%J8+,'

slide-8
SLIDE 8

3/28/11 8

?71'64%",:&%"6%C)"'2%,'")'+Q+36')"'!H':%62)&)F9' ?71'64%",:&%"6%C)"'%&,)'2%,'")'' +Q+36')"'6%8':%62)&)F9' F9@5&?"2724*&51$#?42D*$*535& & B34.3$&4.*&@6G&54"#4:7&"#83#4:7 &

slide-9
SLIDE 9

3/28/11 9

?71,'+M:4+,,'2#F2'&+D+&,')-'N4%#"Z/+4#D+*' ?+84)64):2#3'.%36)4'UN/?.V'+$).+5"-) ' ?71,'3)"C"8+'6)'+M:4+,,'N/?.'+$).+.-)%"*' ,#F"#K3%"6&9'+&+D%6+'6)6%&'@4%#"'&+D+&,')-'N/?. '

_")3G*)="')-'N/?.'#"'?71,'4+*83+,'3)F"#CD+' 4+3)D+49'%"*',9"%:C3':&%,C3#69 '

slide-10
SLIDE 10

3/28/11 10 ?+:4#&9,#"Z+M:4+,,#"F'?71,'4+*83+' ' !H :%62)&)F9'

sNEP NSC side control NSC side Red: A" Green: Tau

  • e#&&',#"F&+')4'3)$@#"%C)"')-'F4)=62'-%36)4,'@+'

@+A+4'D,R'3+&&'%::4)%32T'

  • 7+&+3C)"')-'%::4):4#%6+'3+&&'69:+'''

U7+MB'!:)E'F+")69:+V'

  • 7%-+'F+"+C3'$)*#K3%C)"')-'3+&&,'
  • d+F#)"'6)'@+'64%",:&%"6+*'
  • P$$8"),8::4+,,#)"'4+F#$+"'
  • ?8$@+4')-'3+&&,'6)'@+'64%",:&%"6+*'
  • S)"F'6+4$',84D#D%&O@+"+K6,')-'F4%I'
  • !"9'%*D+4,+'+Q+36,O68$)4,T''

Feng et al., Am. J. AD Other Demen 2009

slide-11
SLIDE 11

3/28/11 11

H$I*5CD#42"& H$5C4:C2$& J2+*&

.4%"G'S%.+4&%B'52/' f1'P4D#"+' 54#"3#:%&'P"D+,CF%6)4' (%62+='N&846)"Zg)"+,B' 52/' f1'P4D#"+' P"D+,CF%6)40',6+$'3+&&,' d#32%4*'N)9*B'52/' ()"%,2'f"#DR'U!8,64%&#%V' P"D+,CF%6)40'6)&+4%"3+' 5+6+4'/)")D%"B'52/' f1'P4D#"+' P"D+,CF%6)40'2E7'3+&&,' _+""+62'_),#GB'(/B'52/' f1'7%"6%'N%4@%4%' P"D+,CF%6)40'$#34)d?!' 768%46'S#:6)"B'(/B'52/' N84"2%$'P",C686+' P"D+,CF%6)40':&%,C3#69' g+%""+'S)4#"FB'52/' 734#::,'P",C686+' P"D+,CF%6)40'$)&R':4)K&+' (%4G'>8,;9",G#B'(/B'52/' f1'7%"'/#+F)' P"D+,CF%6)40':4#$%6+,'

!3G")=&+*F+$+"6, '

Current Lab

Mathew Blurton-Jones Masashi Kitazawa Kim Green Hilda Coria-Martinez Rodrigo Medeiros David Baglietto David Cheng Nicholas Castello Maya Koike Kris Myczek Kristine Freude KC Walls Kara Neely Andrew Tran Meredith Chabrier Adam Pabst Tatiana Estrada Jack Reidling Angela Monroe

Former Lab Members Salvatore Oddo Debbi Morrissette Antonella Caccamo Michael Sy Grace Stutzmann Michael Sugarman Malcolm Leissring Yama Akbari Lauren Billings Tritia Yamasaki Lani Clinton

Funding CIRM NIH AHAF Cure AD

Stem Cell Collaborators Jeanne Loring Stuart Lipton Richard Boyd Mark Tuszynski Ken Kosik Peter Donovan Eliezer Masliah